No-reference image quality assessment (NR-IQA) methods automatically and objectively predict the perceptual quality of images without access to a reference image. Therefore, due to the lack of pristine images in most medical image acquisition systems, they play a major role in supporting the examination of resulting images and may affect subsequent treatment. Their usage is particularly important in magnetic resonance imaging (MRI) characterized by long acquisition times and a variety of factors that influence the quality of images. In this work, a survey covering recently introduced NR-IQA methods for the assessment of MR images is presented. First, typical distortions are reviewed and then popular NR methods are characterized, taking into account the way in which they describe MR images and create quality models for prediction. The survey also includes protocols used to evaluate the methods and popular benchmark databases. Finally, emerging challenges are outlined along with an indication of the trends towards creating accurate image prediction models.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224540 | PMC |
http://dx.doi.org/10.3390/jimaging8060160 | DOI Listing |
Radiol Phys Technol
January 2025
Department of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, 7-2-10 Higashi-ogu, Arakawa, Tokyo, 116-8551, Japan.
In plain radiography, scattered X-ray correction processing (Virtual Grid: VG) is used to estimate and correct scattered rays in images. We developed an objective evaluation system for bedside chest X-ray images using VG and investigated its usefulness. First, we trained the blind/referenceless image spatial quality evaluator (BRISQUE) on 200 images obtained by portable chest radiography.
View Article and Find Full Text PDFMod Pathol
December 2024
Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
For 2 decades, the American Society of Clinial Oncology-College of American Pathologists human epidermal growth factor receptor 2 (HER2) testing criteria have included 0 and 1+ scores, but this distinction was inconsequential. Now, based on the DESTINY Breast-04 Trial (DB-04) results, for patients with metastatic breast cancer it underpins eligibility for trastuzumab-deruxtecan treatment. Discerning 0 from 1+ immunohistochemistry (IHC) staining is challenging, as HER2 low is not a biologically distinct cancer subset, there are no reference standards or controls, and second-tier tests (eg, in situ hybridization) do not apply.
View Article and Find Full Text PDFGenerative Adversarial Networks (GANs) have emerged as a powerful tool in artificial intelligence, particularly for unsupervised learning. This systematic review analyzes GAN applications in healthcare, focusing on image and signal-based studies across various clinical domains. Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, we reviewed 72 relevant journal articles.
View Article and Find Full Text PDFAppl Radiat Isot
March 2025
Department of Radiological Science, Gachon University, 191, Hambakmoero, Yeonsu-gu, Incheon, Republic of Korea. Electronic address:
The purpose of this study was to propose and evaluate an algorithm that maximizes the image quality of gamma-ray images using a cadmium zinc telluride (CZT) photon-counting semiconductor detector (PCSD) under thin detector thickness conditions. In addition to the CZT PCSD, a pixel-matched parallel-hole collimator that can optimize the spatial resolution of gamma-ray images was modeled. A non-local mean (NLM) noise reduction algorithm was applied to the acquired images using Geant4 Application for Tomographic Emission platform to quantitatively evaluate the overall image quality improvement.
View Article and Find Full Text PDFBMC Genomics
November 2024
Research Laboratory of Human Genome and Multifactorial Diseases, Faculty of Pharmacy, University of Monastir, Street Avicenne, Monastir, 5000, Tunisia.
Background: Leber hereditary optic neuropathy (LHON) is a mitochondrial DNA (mtDNA) rare disease due to the pathogenic variant of the NADH dehydrogenase enzyme. LHON is characterized by a sudden central vision loss due to focal degeneration of the retinal ganglion cell layer and optic nerve. Symptoms usually appear between the age of 18 and 35 years.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!